



Corrigendum

Corrigendum to: “The Influence of Baseline Parameters on Changes in IPSS with Dutasteride, Tamsulosin, and Combination Therapy: Two-Year Data from the Combination of Avodart[®] and Tamsulosin (CombAT) Study” [Eur Urol Suppl 2008;7:171 (Abstract no. 403)]

Claus G. Roehrborn^{a,*}, Andrea Tubaro^b, Francesco Montorsi^c, Massimo Maffezzini^d, Thierry Lebret^e, Venancio Chantada^f, Jack Barkin^g, Ramiro Castro^h, Tim Wilsonⁱ

^a Department of Urology, UT Southwestern Medical Center, Dallas, Texas, USA

^b 2nd School of Medicine, La Sapienza University, Rome, Italy

^c Department of Urology, Università Vita Salute San Raffaele, Milan, Italy

^d Department of Urology, Galliera Hospital, Genova, Italy

^e CMC Foch, Service d’Urologie, Suresnes, France

^f Hospital Juan Canalejo 1, La Coruña, Spain

^g CMX Research Inc. & University of Toronto, Toronto, Ontario, Canada

^h GlaxoSmithKline Clinical Development and Medical Affairs, Madrid, Spain

ⁱ Department of Biostatistics, GlaxoSmithKline, Research Triangle Park, NC, USA

The Table 1 belonging to this abstract is placed below.

Table 1 – Adjusted mean changes from baseline to month 24 in IPSS by baseline parameters (ITT, LOCF)

Sub-group	Treatment group	1st subgroup	2nd subgroup	3rd subgroup
Prostate volume tertiles (<42, 42–<58, ≥58 cc)	Tam	–5.0	–4.2	–3.8
	Dut	–4.5	–4.7	–5.5*
	Comb	–6.0* [†]	–6.0* [†]	–6.5* [†]
PSA tertiles (<2.7, 2.7–<4.4, ≥4.4) ng/ml	Tam	–4.5	–4.4	–4.1
	Dut	–4.3	–4.9	–5.4*
	Comb	–6.2* [†]	–6.5* [†]	–5.9*
Previous BPH treatment (alpha blocker, 5ARI or phytotherapy vs. none)	Tam	–4.2	–4.7	
	Dut	–4.9*	–4.8	
	Comb	–6.2* [†]	–6.3* [†]	
Median IPSS (<16, ≥16)	Tam	–1.8	–6.7	
	Dut	–2.1	–7.6*	
	Comb	–3.0* [†]	–9.2* [†]	

DOI of original article: 10.1016/S1569-9056(08)60399-1

* Corresponding author.

E-mail address: claus.roehrborn@utsouthwestern.edu (C.G. Roehrborn).

0302-2838/\$ – see back matter doi:10.1016/j.eururo.2008.06.035

Table 1 (Continued)

Sub-group	Treatment group	1st subgroup	2nd subgroup	3rd subgroup
IPSS (<20, ≥20)	Tam	−2.8	−8.3	
	Dut	−3.1	−9.5*	
	Comb	−4.2 [†]	−11.2 [†]	
Median IPSS QoL (<4, ≥4)	Tam	−3.0	−5.5	
	Dut	−3.4	−6.2*	
	Comb	−4.6 [†]	−7.6 [†]	
Median Qmax (<10.4, ≥10.4 ml/s)	Tam	−4.6	−4.1	
	Dut	−4.9	−4.9*	
	Comb	−6.2 [†]	−6.1 [†]	
Age (<65, ≥65)	Tam	−4.2	−4.4	
	Dut	−5.0*	−4.8	
	Comb	−6.4 [†]	−6.0 [†]	
Median age (<66, ≥66)	Tam	−4.1	−4.5	
	Dut	−4.9*	−4.9	
	Comb	−6.5 [†]	−5.9 [†]	
Race (white, non-white)	Tam	−4.6	−5.3	
	Dut	−4.9	−7.0*	
	Comb	−6.2 [†]	−8.2*	
Median BMI (<26.8, ≥26.8)	Tam	−4.6	−4.0	
	Dut	−5.1	−4.6*	
	Comb	−6.2 [†]	−6.1 [†]	
Median BII (<5, ≥5)	Tam	−2.9	−5.4	
	Dut	−3.6*	−5.9	
	Comb	−4.5 [†]	−7.4 [†]	

**p* < 0.05 vs. tamsulosin; [†]*p* < 0.05 vs. dutasteride.